1023701-01-0

Upstream product

• 106-41-2 4-bromo-phenol 
• 67900-64-5 3-(4-Bromophenoxy)-1-propanol 

Downstream Products

• 1023701-00-9 (S)-2-[3-(4-bromo-phenoxy)-propylamino]-4-methyl-pentanoic acid cyclopentyl ester 
• 1594130-76-3 1-bromo-4-(3,3-difluoropropoxy)benzene 
• 1594128-54-7 C₂₂H₂₇F₂N₃O₃ 

Relevant academic research and scientific papers

NOVEL COMPOUND HAVING AUXIN BIOSYNTHESIS INHIBITORY ACTIVITY, MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF

PROBLEM TO BE SOLVED: To provide a novel compound having an auxin biosynthesis inhibitory activity, and a novel compound having the auxin biosynthesis inhibitory activity with different mechanism of action from conventional auxin biosynthesis inhibitors. SOLUTION: An aspect of the invention relates to a compound represented by the formula (I), wherein n, Ar, A, X1, X2, R1, R2, R3, R4, R5, R6, R7, R8, and R9 have meaning described in the application and the Claims, or a salt thereof, or a solvate thereof. Another aspect of the invention relates to an auxin biosynthesis inhibitors containing the compound represented by the formula (I), or a salt thereof, or a solvate thereof as active ingredients, agricultural applications of the compound, and a manufacturing method of the compound. SELECTED DRAWING: None COPYRIGHT: (C)2019,JPOandINPIT

Access to β-Ketonitriles through Nickel-Catalyzed Carbonylative Coupling of α-Bromonitriles with Alkylzinc Reagents

Herein, we report a nickel-catalyzed carbonylative coupling of α-bromonitriles and alkylzinc reagents with near stoichiometric carbon monoxide to give β-ketonitriles in good yields. The reaction is catalyzed by a readily available and stable nickel(II) pincer complex. The developed protocol tolerates substrates bearing a variety of functional groups, which would be problematic or incompatible with previous synthetic methods. Additionally, we demonstrate the suitability of the method for carbon isotope labeling by the synthesis of 13C-labeled β-ketonitriles and their transformation into isotopically labeled heterocycles.

New pyrrolidine derivatives, pharmaceutical compositions and uses thereof

Pyrrolidine derivatives of the formula and their use as medicaments for the treatment of obesity and type 2 diabetes.

NEW PYRROLIDINE DERIVATIVES AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS

The invention relates to new pyrrolidine derivatives of the formula (I) to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS

Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH-Y-L1-X1-(CH2)Z- wherein: z is 0 or 1; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non- natural alpha amino acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(=O)NR3-, - C(=S)-NR3, -C(=NH)-NR3 or -S(=O)2NR3- wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent linker radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.